After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT),
this therapy has advanced from one that was declared dead in the 1960s to a standard …

Normal male volunteers receiving single doses of 3.45 pgkg Filgrastim by 30-minute
intravenous infusion had a mean serum concentration of 20.8 ng/mL 5 minutes after the end …

Background Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but …

For this study, 118 children with standard-risk acute lymphoblastic leukemia (ALL) were
given randomized assignments to receive native or pegylated Escherichia coli asparaginase …

Background In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells
mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) …

PURPOSE: The purpose of this study was to compare histologic and magnetic resonance
imaging (MRI) evaluation of articular cartilage regeneration in patients with chondral lesions …

Background Bone marrow contains stem cells with the potential to differentiate into mature
cells of various organs. We determined whether circulating stem cells have a similar …

''It seems more than ever likely that blood-derived stem tive capacity. 47-49 In the allogeneic
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …

PURPOSE To investigate the use of a nonmyeloablative fludarabine-based preparative
regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem …

2000 update of recommendations for the use of hematopoietic colony-stimulating factors:
evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth …